Your cart is currently empty!

ISO 21560:2020
ISO 21560:2020 General requirements of tissue-engineered medical products
CDN $115.00
Description
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Edition
1
Published Date
2020-08-31
Status
PUBLISHED
Pages
11
Format 
Secure PDF
Secure – PDF details
- Save your file locally or view it via a web viewer
- Viewing permissions are restricted exclusively to the purchaser
- Device limits - 3
- Printing – Enabled only to print (1) copy
See more about our Environmental Commitment

Abstract
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Previous Editions
Can’t find what you are looking for?
Please contact us at:
Related Documents
-
ISO 5840:2025 Cardiovascular implants – Cardiac valve prostheses – Part 1: General requirements – Amendment 1
0 out of 5CDN $32.00 Add to cart -
ISO 8549:2023 Prosthetics and orthotics – Vocabulary – Part 2: Terms relating to external limb prostheses
0 out of 5CDN $76.00 Add to cart -
ISO 16087:2013 Implants for surgery – Roentgen stereophotogrammetric analysis for the assessment of migration of orthopaedic implants
0 out of 5CDN $115.00 Add to cart -
ISO 5841:2014 Implants for surgery – Cardiac pacemakers – Part 2: Reporting of clinical performance of populations of pulse generators or leads
0 out of 5CDN $233.00 Add to cart